COVID-19 vaccine.The research, which has yet to be peer reviewed, found that the Pfizer-BioNTech vaccine produced a much weaker antibody result in long-term care residents than it did in younger, healthier people.“That is a bit concerning, of course, because the dosing interval in some Canadian provinces has been extended, which probably makes sense for younger people and it’s had a good real-world impact because we’re seeing fewer impacts in long-term care,” research team lead Dr.